Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Gilead hands Arcellx $285M to expand BCMA cell therapy deal
Kite has secured rights to an early-phase BCMA CAR-T candidate and expanded its existing midphase cell therapy collaboration to cover lymphomas.
Nick Paul Taylor
Nov 15, 2023 10:00am
Ultimovacs links BMS-cancer vaccine combo to improved survival
Oct 18, 2023 8:40am
ALX links CD47 drug to improved response rate in solid tumors
Oct 3, 2023 6:15am
Gilead ends phase 3 leukemia trial early after data disappoint
Sep 27, 2023 7:48am
AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space
Sep 25, 2023 7:30am
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO
Sep 22, 2023 9:20am
